Location History:
- Manitoba, CA (2014)
- Winnipeg, CA (2009 - 2016)
Company Filing History:
3 out of 832,812 Years Active: 2009-2016
Title: Mike Gubbins: Innovator in Monoclonal Antibody Research
Introduction
Mike Gubbins is a notable inventor based in Winnipeg, Canada. He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. With a total of 3 patents, Gubbins has focused on innovative solutions for treating infections.
Latest Patents
Gubbins' latest patents include the characterization and isolation of monoclonal antibodies to anthrax protective antigen. Specifically, he has worked on F20G75, F20G76, and F20G77, which exhibit neutralizing activities. These monoclonal antibodies can be utilized as a pharmaceutical composition for individuals suspected of or at risk of anthrax infection. They bind to a specific region of the protective antigen, comprising amino acids 311-316, and can also be part of vaccines designed to immunize individuals against infection.
Career Highlights
Throughout his career, Gubbins has worked with various organizations, including Her Majesty the Queen in Right of Canada, as represented by the Minister. His work has been instrumental in advancing the understanding and treatment of anthrax-related infections.
Collaborations
Gubbins has collaborated with notable coworkers such as Jody Berry and Raymond Tsang. Their combined efforts have contributed to the success of his research and innovations.
Conclusion
Mike Gubbins is a distinguished inventor whose work in monoclonal antibodies has the potential to impact public health significantly. His innovative research continues to pave the way for new treatments and vaccines against serious infections.